Search
for
Sort by
Research 61–90 of 1000+
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
- Update on pulse corticosteroid therapy for the management of alopecia areata
- European expert consensus statement on the systemic treatment of alopecia areata
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Evaluation of serum 25-hydroxy vitamin D levels in alopecia areata of scalp: a cross sectional observational study
- Using artificial intelligence to compute Severity of Alopecia Tool scores
- Five Cases of Severe Alopecia Areata Treated with Gagamhwajung-hwan
- Treatment of severe alopecia areata with oral tofacitinib: A case series
- Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Role of Hair Prostheses (Wigs) in Patients with Severe Alopecia Areata
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Bempikibart shows its potential for hair regrowth in alopecia areata